Comparison Overview

MAST Biosurgery

VS

Stryker

MAST Biosurgery

6749 Top Gun Street, Ste 108, San Diego, CA, 92121, US
Last Update: 2025-05-04 (UTC)
Between 800 and 900

Strong

Leading in the design, development, and production of bioresorbable polymer implants, and emerging new technologies for the use in variety of surgical applications within the biosurgery market. Before the advent of bioresorbable materials, the closure of soft tissue was limited to permanent materials such as nylon sutures. Advances in material sciences led to the development of bioresorbable polymer sutures that met the clinical needs of holding soft tissues together, while serving the patient's need of not remaining permanently in the body. The evolution of bioresorbable polymer technology facilitated the development of large bioresorbable polymer sheets that could span large tissue masses and subsequently hold them in place. The thin sheets facilitate the healing of larger tissue masses and virtually eliminating many adverse effects of permanent implants. Bioresorbable surgical thin sheet for soft tissue applications, made from polylactide (PLA): a copolymer of 70:30 Poly(L-lactide-co-D,L-lactide). Composed of lactic acid similar to that which occurs naturally in the human body, the copolymer maintains its strength during the healing process, and through hydrolysis slowly breaks down into lactic acid molecules. The molecules are ultimately metabolized into carbon dioxide and water and are released from the body through the lungs.

NAICS: 3391
NAICS Definition: Medical Equipment and Supplies Manufacturing
Employees: 18
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Stryker

2825 Airview Boulevard, None, Kalamazoo, MI, US, 49002
Last Update: 2025-08-05 (UTC)

Strong

Between 800 and 900

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at stryker.com and careers.stryker.com. Facts: โ— 2023 Sales: $20.5 billion โ— Industry: Medical Instruments & Supplies โ— Employees: 52,000 worldwide โ— 40 years of sales growth leading up to 2020 โ— 44+ Manufacturing and R&D Locations Worldwide โ— $1.4 billion spent on research and development in 2023 โ— ~12,900 patents owned globally in 2023 โ— Products sold in ~75 countries โ— Fortune 500 Company โ— 7 consecutive years as one of Fortune's World's Best Workplaces Strykerโ€™s social media community guidelines: https://www.stryker.com/content/m/legal/social-media-community-guidelines/en/index.html Notice Regarding Employee Conduct on Facebook/LinkedIn Meta/LinkedIn does not permit employers to verify or validate โ€œemployeesโ€ in the (META: โ€œWorks atโ€ LinkedIn: โ€œExperienceโ€) section of usersโ€™ profiles. Please be aware that the views expressed by individuals on their personal accounts and do not necessarily represent the views of our company. If you encounter any issues with a person claiming to be our employee, we recommend using the โ€œReport Profileโ€ feature. If youโ€™d like to report concerns to our Ethics Hotline, you may do so at: https://app.convercent.com/en-us/LandingPage/b6bb4e84-9fcb-ea11-a974-000d3ab9f296

NAICS: 3391
NAICS Definition: Medical Equipment and Supplies Manufacturing
Employees: 47,772
Subsidiaries: 39
12-month incidents
0
Known data breaches
1
Attack type number
1

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/defaultcompany.jpeg
MAST Biosurgery
โ€”
ISO 27001
Not verified
โ€”
SOC 2
Not verified
โ€”
GDPR
No public badge
โ€”
PCI DSS
No public badge
https://images.rankiteo.com/companyimages/stryker.jpeg
Stryker
โ€”
ISO 27001
Not verified
โ€”
SOC 2
Not verified
โ€”
GDPR
No public badge
โ€”
PCI DSS
No public badge
Compliance Summary
MAST Biosurgery
100%
Compliance Rate
0/4 Standards Verified
Stryker
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Medical Equipment Manufacturing Industry Average (This Year)

No incidents recorded for MAST Biosurgery in 2025.

Incidents vs Medical Equipment Manufacturing Industry Average (This Year)

No incidents recorded for Stryker in 2025.

Incident History โ€” MAST Biosurgery (X = Date, Y = Severity)

MAST Biosurgery cyber incidents detection timeline including parent company and subsidiaries

Incident History โ€” Stryker (X = Date, Y = Severity)

Stryker cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/defaultcompany.jpeg
MAST Biosurgery
Incidents

No Incident

https://images.rankiteo.com/companyimages/stryker.jpeg
Stryker
Incidents

Date Detected: 5/2024
Type:Breach
Attack Vector: Unauthorized Access
Blog: Blog

FAQ

Both MAST Biosurgery company and Stryker company demonstrate a comparable AI risk posture, with strong governance and monitoring frameworks in place.

Stryker company has historically faced a number of disclosed cyber incidents, whereas MAST Biosurgery company has not reported any.

In the current year, Stryker company and MAST Biosurgery company have not reported any cyber incidents.

Neither Stryker company nor MAST Biosurgery company has reported experiencing a ransomware attack publicly.

Stryker company has disclosed at least one data breach, while MAST Biosurgery company has not reported such incidents publicly.

Neither Stryker company nor MAST Biosurgery company has reported experiencing targeted cyberattacks publicly.

Neither MAST Biosurgery company nor Stryker company has reported experiencing or disclosing vulnerabilities publicly.

Stryker company has more subsidiaries worldwide compared to MAST Biosurgery company.

Stryker company employs more people globally than MAST Biosurgery company, reflecting its scale as a Medical Equipment Manufacturing.

Latest Global CVEs (Not Company-Specific)

Description

An issue was discovered in chinabugotech hutool before 5.8.4 allowing attackers to execute arbitrary expressions that lead to arbitrary method invocation and potentially remote code execution (RCE) via the QLExpressEngine class.

Description

A weakness has been identified in JeecgBoot up to 3.8.2. The impacted element is an unknown function of the file /sys/role/exportXls. This manipulation causes improper authorization. It is possible to initiate the attack remotely. The exploit has been made available to the public and could be exploited. The vendor was contacted early about this disclosure but did not respond in any way.

Risk Information
cvss2
Base: 4.0
Severity: LOW
AV:N/AC:L/Au:S/C:P/I:N/A:N
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A security flaw has been discovered in JeecgBoot up to 3.8.2. The affected element is an unknown function of the file /sys/user/exportXls of the component Filter Handler. The manipulation results in improper authorization. The attack may be performed from remote. The exploit has been released to the public and may be exploited. The vendor was contacted early about this disclosure but did not respond in any way.

Risk Information
cvss2
Base: 4.0
Severity: LOW
AV:N/AC:L/Au:S/C:P/I:N/A:N
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A vulnerability was identified in JeecgBoot up to 3.8.2. Impacted is an unknown function of the file /sys/tenant/deleteBatch. The manipulation of the argument ids leads to improper authorization. The attack is possible to be carried out remotely. The complexity of an attack is rather high. The exploitability is considered difficult. The exploit is publicly available and might be used. The vendor was contacted early about this disclosure but did not respond in any way.

Risk Information
cvss2
Base: 2.1
Severity: HIGH
AV:N/AC:H/Au:S/C:P/I:N/A:N
cvss3
Base: 3.1
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:U/C:L/I:N/A:N
cvss4
Base: 2.3
Severity: HIGH
CVSS:4.0/AV:N/AC:H/AT:N/PR:L/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A vulnerability was determined in JeecgBoot up to 3.8.2. This issue affects some unknown processing of the file /api/getDepartUserList. Executing manipulation of the argument departId can lead to improper authorization. The attack can be executed remotely. This attack is characterized by high complexity. The exploitability is assessed as difficult. The exploit has been publicly disclosed and may be utilized. The vendor was contacted early about this disclosure but did not respond in any way.

Risk Information
cvss2
Base: 2.1
Severity: HIGH
AV:N/AC:H/Au:S/C:P/I:N/A:N
cvss3
Base: 3.1
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:U/C:L/I:N/A:N
cvss4
Base: 2.3
Severity: HIGH
CVSS:4.0/AV:N/AC:H/AT:N/PR:L/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X